How Is Tetratherix Turning $4.6m Loss into Clinical and Commercial Momentum?

• Statutory loss of AUD 4.6 million in H1 FY26 reflecting expanded R&D and manufacturing
• Progression of TetraDerm and Tutelix clinical trials with major safety and efficacy milestones
• Exclusive global supply agreement signed with Henry Schein for bone regeneration product Tegenix
• Strategic licensing deal with BioOptix and partnership with Alcon to accelerate ophthalmic biomaterials